BIIB021 (Standard)

BIIB021 (Standard) is the analytical standard of BIIB021. This product is intended for research and analytical applications. BIIB021 (CNF2024) is an orally active, fully synthetic inhibitor of HSP90 with a Ki and an EC50 of 1.7 nM and 38 nM, respectively[1].

Product Specifications

CAS Number

[848695-25-0]

Product Name Alternative

CNF2024 (Standard)

UNSPSC

12352005

Target

Autophagy; HSP; Reference Standards

Related Pathways

Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Others

Field of Research

Cancer

Smiles

ClC1=C2C(N(C=N2)CC3=C(C(OC)=C(C=N3)C)C)=NC(N)=N1

Molecular Formula

C14H15ClN6O

Molecular Weight

318.76

References & Citations

[1]Lundgren, Karen., et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Molecular Cancer Therapeutics (2009), 8 (4), 921-929.|[2]B?ll B, et al. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity. Clin Cancer Res. 2009 Aug 15;15 (16) :5108-16.|[3]Yin X, et al. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int J Cancer. 2010 Mar 1;126 (5) :1216-25|[4]Zhang H, et al. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance. Int J Cancer. 2010 Mar 1;126 (5) :1226-34